| |
| |
|
| Insider
Information: |
Hagan Joseph P |
| Relationship: |
Director |
| City: |
La Jolla |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
104,599 |
|
|
Indirect Shares
|
225,674 |
|
|
| Direct
Value |
$189,035 |
|
|
|
Indirect Value
|
$498,740 |
|
|
| Total
Shares |
330,273 |
|
|
| Total
Value |
$687,775 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
-1.0
|
| Percentage
Gain/Loss : |
 -24.2%
|
-26.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Orexigen Therapeutics, Inc. |
OREX |
Sr. VP, Corporate Deve... |
2014-09-15 |
13,026 |
2012-06-27 |
0 |
Premium* |
|
|
Regulus Therapeutics Inc. |
RGLS |
Chief Executive Office... |
2024-01-18 |
57,112 |
2020-12-04 |
225,674 |
Premium* |
|
|
Zosano Pharma Corp |
ZSAN |
Director |
2021-06-10 |
22,500 |
2021-06-10 |
0 |
Premium* |
|
|
Aurinia Pharmaceuticals Inc |
AUPH |
Director |
2023-05-19 |
11,961 |
2022-01-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
45 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AUPH |
Aurinia Pharmaceuticals I... |
Director |
– • – |
2022-01-03 |
4 |
AS |
$22.58 |
$903,650 |
D/D |
(40,000) |
3,500 |
0 |
% |
|
| AUPH |
Aurinia Pharmaceuticals I... |
Director |
– • – |
2022-01-03 |
4 |
OE |
$5.08 |
$203,200 |
D/D |
40,000 |
43,500 |
0 |
- |
|
| AUPH |
Aurinia Pharmaceuticals I... |
Director |
– • – |
2023-05-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,733 |
12,233 |
0 |
- |
|
| AUPH |
Aurinia Pharmaceuticals I... |
Director |
– • – |
2023-05-19 |
4 |
S |
$10.58 |
$2,878 |
D/D |
(272) |
11,961 |
0 |
% |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2012-06-27 |
4 |
OE |
$1.66 |
$116,200 |
D/D |
70,000 |
70,000 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2012-06-27 |
4 |
AS |
$4.90 |
$368,000 |
D/D |
(70,000) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2012-06-28 |
4 |
AS |
$5.90 |
$153,400 |
D/D |
(26,000) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2012-06-28 |
4 |
OE |
$1.66 |
$43,160 |
D/D |
26,000 |
26,000 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2012-06-29 |
4 |
AS |
$6.30 |
$75,600 |
D/D |
(12,000) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2012-06-29 |
4 |
OE |
$1.66 |
$19,920 |
D/D |
12,000 |
12,000 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2012-07-13 |
4 |
AS |
$6.70 |
$203,000 |
D/D |
(30,000) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2012-07-13 |
4 |
OE |
$1.66 |
$49,800 |
D/D |
30,000 |
30,000 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2013-05-28 |
4 |
AS |
$7.00 |
$196,000 |
D/D |
(28,000) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2013-05-28 |
4 |
OE |
$1.66 |
$46,480 |
D/D |
28,000 |
28,000 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2013-07-26 |
4 |
AS |
$7.40 |
$74,000 |
D/D |
(10,000) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2013-07-26 |
4 |
OE |
$1.66 |
$16,600 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2013-07-31 |
4 |
AS |
$7.80 |
$93,600 |
D/D |
(12,000) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2013-07-31 |
4 |
OE |
$1.66 |
$19,920 |
D/D |
12,000 |
12,000 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Chief Business Officer |
• – – |
2013-11-29 |
4 |
A |
$5.34 |
$21,253 |
D/D |
3,980 |
3,980 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
Sr. VP, Corporate Development |
• – – |
2014-09-15 |
4 |
B |
$4.69 |
$23,450 |
D/D |
5,000 |
13,026 |
2.74 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
Chief Operating Officer |
• – – |
2016-03-03 |
4 |
B |
$7.19 |
$71,900 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
President and CEO |
• • – |
2017-07-25 |
4 |
B |
$0.91 |
$200,000 |
D/D |
219,780 |
241,297 |
2.81 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
President and CEO |
• • – |
2019-02-05 |
4 |
A |
$0.95 |
$61,750 |
D/D |
65,000 |
84,148 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
President and CEO |
• • – |
2019-04-01 |
4 |
AS |
$0.98 |
$5,731 |
D/D |
(5,842) |
31,348 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
President and CEO |
• • – |
2019-05-07 |
4 |
B |
$1.08 |
$35,850 |
D/D |
33,194 |
64,542 |
2.81 |
- |
|
45 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
